Physician profile
Michael Jacobs
NPI 1710522313
$3,019.94
in general payments reported to CMS, 2019-2025
22 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $402 · 2023: $173 · 2024: $829 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $510.11 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $506.41 | 2021-2022 | |
| Abbvie INC. | $368.19 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.41 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $264.24 | 2022-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $177.67 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $175.49 | 2024-2025 | Cobenfy |
| Corium, LLC | $148.33 | 2023-2025 | Azstarys |
| Lundbeck LLC | $107.49 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $70.88 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $69.07 | 2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $53.79 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $52.51 | 2022-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $40.88 | 2022 | |
| Tris Pharma INC | $37.87 | 2022-2023 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $37.37 | 2025 | Relexxii |
| Alkermes, INC. | $28.88 | 2023 | Aristada, Lybalvi |
| Cardiva Medical, INC. | $25.15 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic, INC. | $18.49 | 2025 | Micra |
| Axsome Therapeutics, INC. | $17.56 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $11.60 | 2021 | |
| Eisai INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.